Your browser doesn't support javascript.
loading
Analysis of Clinical Efficacy and Safety of Ustekinumab in Treatment of Inflammatory Bowel Disease / 胃肠病学
Chinese Journal of Gastroenterology ; (12): 711-716, 2022.
Artículo en Chino | WPRIM | ID: wpr-1016056
ABSTRACT

Background:

The efficacy of ustekinumab (UST) in the treatment of patients with inflammatory bowel disease (IBD) has been affirmed abroad, but its efficacy and safety have not been reported in China due to its short term of use.

Aims:

To analyze the clinical efficacy and safety of UST in the treatment of IBD.

Methods:

The clinical data of IBD patients treated with UST from November 2020 to June 2022 in the First Affiliated Hospital of Air Force Medical University were analyzed retrospectively.

Results:

A total of 46 patients with IBD treated with UST were enrolled, including 41 patients with Crohn’s disease (CD) and 5 patients with ulcerative colitis (UC). At the 8

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Gastroenterology Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Chinese Journal of Gastroenterology Año: 2022 Tipo del documento: Artículo